Gnosis presents a new study during the 6th Probiotics, Prebiotics & New Foods Meeting in Rome supporting Dietary Supplementation with *S. boulardii* and its potential role in managing Metabolic Syndrome in Obesity.

**DESIÓ, Italy – August 2nd, 2011**

Gnosis S.p.A will sponsor and participate in the “6th Probiotics, Prebiotics & New Foods” symposium held in Rome September 11-13 2011 at the Urbaniana University. Gnosis will present studies on dietary supplementation with *Saccharomyces boulardii* as a novel strategy to improve the Metabolic Syndrome in an animal model of obesity. The important scientific work will be presented to the eminent audience by Prof. Ignazio Castagliuolo, Associate Professor of Microbiology of Padua University, Italy.

Gnosis Biooptima Saccharomyces boulardii is produced under a patent protected process and advanced drying technologies. With this presentation the company continues its commitment to identify and characterized new and unique health and therapeutic benefits and applications further differentiating it in the market place.

Gnosis has matured several years of experience in the production of cGMP grade *Saccharomyces boulardii*. This probiotic yeast is commercialized under the probiotic brand name of Biooptima, serving worldwide pharmaceutical and nutritional markets (dairy, dietary supplements and food products). The continuous, large-scale and dedicated production line with state-of-the-art manufacturing equipment allow us to play a leadership role in worldwide market with added value of our product.

The meeting has been organized under the patronage of “Italian Academy for the study of Intestinal Microbiota, SIGE – Italian Gastroenterology Society”, SINUT - Italian Society of Nutraceuticals, ESPGHAN - European Society for Paediatric Gastroenterology, Hepatology and Nutrition and SIGENP – Italian Gastroenterology and Hepatology Society and Paediatric Nutrition.

The International conference, that takes place every two years, brings together highly qualified speakers to explore recent research and scientific advances related to probiotics, prebiotics and new foods and to address claims substantiation, regulatory and technology issues for innovative industrial applications in this fields. New scientific approaches are driving the international scientific community to develop novel sophisticated and refined techniques to clarify how these microorganisms work in-vivo, how the benefits they bring to the
human body are regulated and how the characterized gut microflora interacts with probiotics and their microelements composition.

Member of ISAPP - International Scientific Association for Probiotics and Prebiotic, Gnosis maintains close collaborations with recognized scientific organizations and probiotic experts with a constant investment in sustaining effectiveness of product through clinical studies. Manufacturing capability has been rising in the last year, with a containment of production cost and an improved efficiency, mindful of the need to manage the business sustainably.

The persistent strong interest of health industry on probiotics market reflects the impressive trend of growth registered worldwide expected to cross US$28.8 billion revenues by 2015, according to New Report by Global Industry Analysts, Inc.. Consumers are more conscious about their health and the importance of prevention; they are becoming increasingly aware of the favorable benefits of the “friendly” bacteria in keeping a balanced intestinal flora, helping digestion of food, enforcing the immune system, fighting harmful bacteria and producing vitamins.

For more information contact:
marketing@gnosis-bio.com

Useful links:
http://probiotics-prebiotics-newfood.org/
http://www.isapp.net/default.asp
www.gnosis-bio.com